Alzheimer's Disease Articles & Pharmaceutical Insights | Pharma’s Almanac

Subscribe

Subscribe for the Newsletter

Mobile Navigation

Articles
Expert Interviews
Roundtable
Press Releases
Videos
Market Research

Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing

Alzheimer's Disease

Sort By

Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.

Explore

About Us Nice Insight That's Nice

Reach Our Team

Contact Us Advertise LinkedIn

My Account

Subscribe for the newsletter

© 2026 PHARMA'S ALMANAC. All rights reserved.

Privacy Policy Terms And Conditions

(6)

1 / 1

Using Real-World Data to Close Treatment Gaps in Alzheimer’s Disease and Related Dementias

Dementia

Using Real-World Data to Close Treatment Gaps in Alzheimer’s Disease and Related Dementias

PointClickCare Life Sciences

PAO-12-25-CL-03Dec 11, 2025

Bridging the Gap: Advancing Access to New Medications for Older Adults in Long-Term Care

Health Equity

Bridging the Gap: Advancing Access to New Medications for Older Adults in Long-Term Care

PointClickCare Life Sciences

PAO-11-25-CL-07Nov 24, 2025

Alzheimer's

Enhanced Genomics and The ALBORADA Drug Discovery Institute Partner to Accelerate Alzheimer's Drug Discovery

Enhanced Genomics

PR-06-25-NI-08Jun 24, 2025

Clinical Results

ACADIA Pharmaceuticals Presents Positive Top-line Results from Dementia-Related Psychosis Trial

Acadia Pharmaceuticals

PR-M12-19-NI-012Dec 6, 2019

Single Gene Identified as Culprit in Early-Onset Dementia

Dementia

Single Gene Identified as Culprit in Early-Onset Dementia

Pharma's Almanac

PAO-M12-18-NI-016Dec 19, 2018

Drug Designation

Alector Receives Orphan Drug Designation from the U.S. FDA for AL001 for the Treatment of Frontotemporal Dementia

Alector

PR-M08-18-NI-080Aug 21, 2018

1 / 1